NCT02048813
Clinical Trial Information
Trial Number: NCT02048813 (ClinicalTrials.gov)
Disease Type:
- Hematopoietic Neoplasm/Leukemia - Chronic Lymphoid Leukemia
Trial Title:
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
Study ID:
E1912
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT02048813-D3 | There are three different submissions (each with one dataset) for PMID 31365801 from ECOG-ACRIN trial E1912. This dataset NCT02048813-D3 contains toxicity data as shown in supplemental Table S7 of the paper. Dataset NCT02048813-D1 contains baseline, treatment, and efficacy data. Dataset, NCT02048813-D2, contains toxicity data as shown in Table 2 of the paper. |
| NCT02048813-D2 | There are three different submissions (each with one dataset) for PMID 31365801 from ECOG-ACRIN trial E1912. This dataset, NCT02048813-D2, contains toxicity data as shown in Table 2 of the paper. Dataset NCT02048813-D1 contains baseline, treatment, and efficacy data. Dataset NCT02048813-D3 contains toxicity data as shown in supplemental Table S7 of the paper. |
| NCT02048813-D1 | There are three different submissions (each with one dataset) for PMID 31365801 from ECOG-ACRIN trial E1912. This dataset, NCT02048813-D1, contains baseline, treatment, and efficacy data. Dataset NCT02048813-D2 contains toxicity data as shown in Table 2 of the paper. Dataset NCT02048813-D3 contains toxicity data as shown in supplemental Table S7 of the paper. |
Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security
U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov
NIH…Turning Discovery Into Health®